GE HealthCare announced on September 10 that it entered into an agreement to acquire AI-powered imaging analysis company Icometrix.
Founded in 2011, Icometrix is a healthcare technology company developing imaging analysis technology for neurological disorders such as Alzheimer’s disease.
GE Healthcare, a subsidiary of General Electric (GE), is an American multinational medical technology company headquartered in Chicago, Illinois. It was spun-off from GE on January 4, 2023, with GE retaining 13.5% ownership. GE HealthCare provides digital infrastructure, data analytics and decision support tools designed to help in the diagnosis, treatment and monitoring of patients.
The deal remains subject to customary closing conditions, including regulatory approvals. The companies declined to disclose the financial details, but GE HealthCare plans to fund the deal with cash on hand.
GE HealthCare said its planned acquisition aligns with its precision care strategy. It expects the deal to strengthen its clinical decision support applications for timely diagnosis and monitoring through the neuro treatment pathways. Financial terms of the deal were not disclosed.
“This effort marks a pivotal step in our journey to advance precision care in neurology,” said Roland Rott, president and CEO, Imaging at GE HealthCare. “By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.”
According to data captured in the LevinPro HC database, this transaction marks the 88th Laboratories, MRI and Dialysis transaction of the year, and the 48th in the diagnostic specialty. Throughout all of 2024, there were 122 Laboratories, MRI and Dialysis transactions, 64 of them diagnostic deals.
